Sangamo Therapeutics Inc (SGMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a clinical stage biopharmaceutical company which focuses on the research and development and commercialization of engineered DNA-binding proteins (ZFPs) for gene regulation and therapeutic genome editing. The ZFPs can be engineered to make ZFP nucleases (ZFNs), proteins that can modify DNA sequences in a variety of ways; and ZFP transcription factors (ZFP TFs), proteins that are used to turn genes on or off. ZFP Therapeutics has applications in areas such as human therapeutics, research reagents, plant agriculture, cell-line engineering and production of transgenic animals. Sangamo’s pipeline encompasses clinical candidates targeted at the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), gaucher disease, fabry disease and many others. Sangamo offers proprietary In Vivo Protein Replacement Platform (IVPRP) approach in for addressing hemophilia A and B and other monogenic diseases. The company has subsidiaries in the UK and the US. Sangamo is headquartered in Richmond, California, the US.
Sangamo Therapeutics Inc Key Recent Developments
Mar 29,2017: Sangamo Therapeutics Announces Presentation of New Data Demonstrating Significant Reduction of Tau Expression Using Proprietary ZFP Gene Regulation Technology
Feb 28,2017: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results
Feb 27,2017: Sangamo Therapeutics Announces Chief Financial Officer Succession
Jan 10,2017: Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering
Jan 06,2017: Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Sangamo Therapeutics Inc - Key Facts 6
Sangamo Therapeutics Inc - Key Employees 7
Sangamo Therapeutics Inc - Key Employee Biographies 8
Sangamo Therapeutics Inc - Major Products and Services 10
Sangamo Therapeutics Inc - Pharmaceutical Pipeline Products Data 11
Sangamo Therapeutics Inc, Pipeline Products by Therapy Area 11
Sangamo Therapeutics Inc, Pipeline Products by Development Phase 11
Sangamo Therapeutics Inc - History 13
Sangamo Therapeutics Inc - Company Statement 16
Sangamo Therapeutics Inc - Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Section 2 – Company Analysis 20
Sangamo Therapeutics Inc - Business Description 20
Sangamo Therapeutics Inc - Corporate Strategy 21
Sangamo Therapeutics Inc - SWOT Analysis 22
SWOT Analysis - Overview 22
Sangamo Therapeutics Inc - Strengths 22
Sangamo Therapeutics Inc - Weaknesses 23
Sangamo Therapeutics Inc - Opportunities 24
Sangamo Therapeutics Inc - Threats 25
Sangamo Therapeutics Inc - Key Competitors 26
Section 3 – Company Financial Ratios 27
Financial Ratios - Capital Market Ratios 27
Financial Ratios - Annual Ratios 28
Performance Chart 30
Financial Performance 30
Financial Ratios - Interim Ratios 31
Financial Ratios - Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34
Sangamo Therapeutics Inc, Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
Mar 29, 2017: Sangamo Therapeutics Announces Presentation of New Data Demonstrating Significant Reduction of Tau Expression Using Proprietary ZFP Gene Regulation Technology 36
Feb 28, 2017: Sangamo Therapeutics Reports Fourth Quarter And Full Year 2016 Financial Results 37
Feb 27, 2017: Sangamo Therapeutics Announces Chief Financial Officer Succession 39
Jan 10, 2017: Sangamo Therapeutics Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering 40
Jan 06, 2017: Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies 41
Dec 01, 2016: Sangamo BioSciences announces management changes 42
Dec 01, 2016: Sangamo BioSciences Makes Key Leadership Appointments To Strengthen Clinical And Commercial Capabilities 43
Nov 30, 2016: Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ 44
Nov 17, 2016: Genetically Engineered T Cells Render HIV's Harpoon Powerless 45
Oct 26, 2016: Sangamo BioSciences Reports Third Quarter 2016 Financial Results 47
Section 6 – Appendix 49
Methodology 49
Ratio Definitions 49
About GlobalData 53
Contact Us 53
Disclaimer 53List of Tables
Sangamo Therapeutics Inc, Key Facts 6
Sangamo Therapeutics Inc, Key Employees 7
Sangamo Therapeutics Inc, Key Employee Biographies 8
Sangamo Therapeutics Inc, Major Products and Services 10
Sangamo Therapeutics Inc, Number of Pipeline Products by Development Stage 12
Sangamo Therapeutics Inc, History 13
Sangamo Therapeutics Inc, Subsidiaries 19
Sangamo Therapeutics Inc, Key Competitors 26
Sangamo Therapeutics Inc, Ratios based on current share price 27
Sangamo Therapeutics Inc, Annual Ratios 28
Sangamo Therapeutics Inc, Annual Ratios (Cont...1) 29
Sangamo Therapeutics Inc, Interim Ratios 31
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34
Sangamo Therapeutics Inc, Recent Deals Summary 35
Currency Codes 49
Capital Market Ratios 49
Equity Ratios 50
Profitability Ratios 50
Cost Ratios 51
Liquidity Ratios 51
Leverage Ratios 52
Efficiency Ratios 52List of Figures
Sangamo Therapeutics Inc, Pipeline Products by Therapy Area 11
Sangamo Therapeutics Inc, Pipeline Products by Development Phase 11
Sangamo Therapeutics Inc, Performance Chart (2012 - 2016) 30
Sangamo Therapeutics Inc, Ratio Charts 32
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Sangamo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 34
Precision Biosciences Inc
Pfizer Inc
Novo Nordisk Pharmaceuticals Inc
Novartis Corp
Merck & Co Inc
Genzyme Corp
Editas Medicine Inc
Amgen Inc
